Related Experiment Video
Updated: Jul 15, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Use of meningococcal vaccines in the United States
Oleg Bilukha1, Nancy Messonnier, Marc Fischer
1Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract:
In January 2005, Food and Drug Administration licensed a new tetravalent (serogroups A, C, Y, W-135) meningococcal conjugate vaccine ([MCV4] Menactra) for use in persons 11-55 years of age. In February 2005, CDC's Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of adolescents and college freshmen living in dormitories with MCV4. The manufacturer started shipments of MCV4 in March 2005. MCV4 should become a key addition to existing meningococcal disease prevention measures.
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Cryptococcal Meningitis
Vaccinations
Bacterial Meningitis II: Pathophysiology
Viral Meningitis

